Cardiff Oncology reports Q3 EPS (22c), consensus (28c)

Reports Q3 revenue $141,000, consensus $60,000. As of September 30, 2023, Cardiff Oncology had approximately $81.4M in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the third quarter of 2023 was approximately $8M, an increase of approximately $0.5M from $7.5M for the same period in 2022. Based on its current expectations and projections, the company believes its current cash resources are sufficient to fund its operations into 2025.